Cargando…
Targeting mutant p53 for cancer therapy: direct and indirect strategies
TP53 is a critical tumor-suppressor gene that is mutated in more than half of all human cancers. Mutations in TP53 not only impair its antitumor activity, but also confer mutant p53 protein oncogenic properties. The p53-targeted therapy approach began with the identification of compounds capable of...
Autores principales: | Hu, Jiahao, Cao, Jiasheng, Topatana, Win, Juengpanich, Sarun, Li, Shijie, Zhang, Bin, Shen, Jiliang, Cai, Liuxin, Cai, Xiujun, Chen, Mingyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480024/ https://www.ncbi.nlm.nih.gov/pubmed/34583722 http://dx.doi.org/10.1186/s13045-021-01169-0 |
Ejemplares similares
-
Development and Validation of a Nomogram for Predicting Survival in Gallbladder Cancer Patients With Recurrence After Surgery
por: Chen, Mingyu, et al.
Publicado: (2021) -
Development of synthetic lethality in cancer: molecular and cellular classification
por: Li, Shijie, et al.
Publicado: (2020) -
Comparison of Outcomes After Primary Laparoscopic Versus Open Approach for T1b/T2 Gallbladder Cancer
por: Cao, Jiasheng, et al.
Publicado: (2021) -
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
por: Topatana, Win, et al.
Publicado: (2020) -
Inhibition of AMPK/PFKFB3 mediated glycolysis synergizes with penfluridol to suppress gallbladder cancer growth
por: Hu, Jiahao, et al.
Publicado: (2022)